A recent study conducted at The Saban Research Institute in Children’s Hospital Los Angeles by a Barbra Driscoll, Ph.D. has shown for the first time that inhaled Resveratrol therapy effectively slows down aging-related deteriorative lung progression in a mouse.
Lung senescence, characterized by a decrease in volume of the thoracic cavity, decreased lung volumes, changes in muscles that support respiration, airspace enlargementetc. poses a major risk for acquiring Chronic Human Lung Disease.
The lungs of young healthy individuals are quite adept at handling strenuous activities in a seamless and efficient fashion. However, as a consequence of natural aging, lung aging also occurs at a steady irreversible rate. Subsequently, the deterioration in lung function follows suit which eventually leads to a less than ideal quality of life. This progression is dependent on both environmental and genetic functions.
There are some treatments that could alleviate the symptoms, aging-related lung dysfunction is irreversible and with it come increased rate of mortality and morbidity. The body is then vulnerable to diseases which include chronic obstructive pulmonary disease or COPD which is usually accompanied with chronic bronchitis and emphysema.
Resveratrol or RSL–a chemical present in red wine, serves as an antimicrobial substance in plants where it defends against infections and changes as a result of stress. The chemical has previously been shown to reduce oxidative stress, enhance myogenesis and hypertrophy, restore mitochondrial function and promote muscle metabolism when ingested orally.
Preventative oral treatment using RSL was a new method used by the research team as a possible way of slowing aging-related lung degeneration and structure. Case in point, this measure works by sustaining AEC2 or alveolar epithelial type two cells which are on the edge of alveoli—the airsacs in the lungs that facilitate gaseous exchange, and yield a surfactant which further promotes effective and efficient breathing.
The researchers employed a fast aging mouse model to find out if using inhaled RSL could slow down the compounded aging-related deteriorative changes in lung tissue. The subjects of treatment received either intratracheal instillation each month for three months or Resveratrol. After 30 days of the last treatment, the test subjects were evaluated for lung function and AEC2 gene expression as pertaining to any injury.
The researchers discovered that the prophylactic oral treatment using RSL could significantly reduce the rate at which lung function decreased, reduced the rate of alveolar inflammation and reduced the DNA damage of AEC2 gene which occurs at the onset of lung senescence. The researchers concluded that the direct administration of resveratrol could be an effective countermeasure for lung aging thereby reducing the risk of developing Chronic lung disease.
According to Barbra Driscoll, the innate degeneration of the human lung usually takes place overtime—decades, the damage to lung tissue is akin to the lung tissue destruction as a result of respiratory affliction in premature infants before their lung has matured. She added that the aim of the research was to identify a possible way to strengthen and protect young human lungs before any major damage occurred.
You can read more about the study in the journal Thorax.
Researchers show that the direct administration of resveratrol could be an effective countermeasure for lung aging thereby reducing the risk of developing Chronic lung disease.